Publications
Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
N Engl J Med 2021;385:2252–63 doi: 10.1056/NEJMoa2110956
Finerenone has desirable effects on cardiorenal outcomes in patients with stage 3 or 4 chronic kidney disease (CKD), type 2 diabetes and severely elevated albuminuria. The outcomes of the use of finerenone are unclear in patients with type 2 diabetes and a wider range of CKD.
Keywords:
Effects of canagliflozin with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c disease duration and treatment intensity: results from the CANVAS program
Diabetologia. 2021;64:2402–14 doi.org/10.1007/s00125-021-05524-1
This study by Young et al. shows canagliflozin to have beneficial CV and kidney outcomes in patients with T2DM across a range of diabetes complexities with an underlying risk of CV disease.
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: A prespecified analysis of the DAPA-CKD trial
Nephrol Dial Transplant. 2021 Nov 25;gfab335. DOI: 10.1093/ndt/gfab335.
This study by Wheeler et al. found that dapagliflozin numerically, but not significantly, reduced the rate of chronic decline of eGFR compared to placebo among DAPA-CKD participants with FSGS.